SKYE

Skye Bioscience, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website kyebioscience.com
Employees(FY) 11
ISIN US83086J2006

Performance

-20.59%

-7.56%

-12.3%

-64.48%

+57.35%

YTD

+152.88%

Profile

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Advanced Technical Analysis

Technical Analysis of SKYE 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors, as the prevailing trend appea...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SKYE

Stock Rank

Recent News & Updates

2024-11-17 18:00
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences(Globenewswire)
2024-11-14 18:45
Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond(Yahoo Finance)
2024-11-13 18:00
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor(Globenewswire)
2024-11-07 03:01
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights(Globenewswire)
2024-11-03 18:00
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model(Globenewswire)
2024-10-31 19:00
Skye Bioscience to Announce Third Quarter 2024 Results(Globenewswire)
2024-10-28 19:00
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board(Globenewswire)
2024-10-20 19:00
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences(Globenewswire)
2024-09-22 19:00
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan(Globenewswire)
2024-09-02 19:00
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer(Globenewswire)
2024-08-25 19:00
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences(Globenewswire)
2024-08-23 06:45
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-08-21 19:00
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity(Globenewswire)
2024-08-09 05:59
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights(Globenewswire)
2024-07-23 19:30
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND Phase 2 Trial of Nimacimab for Obesity(Globenewswire)
2024-07-23 18:00
Skye Bioscience Hosts Virtual KOL Event, "Metabolic Rewiring with CB1 Inhibition," and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints(Globenewswire)
2024-07-10 19:15
Skye Bioscience to Host Virtual KOL Event, Metabolic Rewiring with CB1 Inhibition, on July 24th(Globenewswire)
2024-07-10 19:00
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab(Globenewswire)
2024-07-02 19:00
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors(Globenewswire)
2024-06-30 23:13
Google DeepMind CEO: 'This Is the Next $100 Billion AI Business'(Investorplace)
2024-06-30 19:00
Skye Bioscience Added to Russell 2000 and Russell 3000 Indexes(Globenewswire)
2024-06-24 19:00
Skye BioScience Participating in Piper Sandler Virtual Obesity Day(Globenewswire)
2024-06-09 20:22
Skye Bioscience ends eye disease R&D efforts after glaucoma drug's phase 2 fail(Fiercebiotech)
2024-06-09 19:00
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program(Globenewswire)
2024-06-02 19:00
Skye Bioscience to Present at Jefferies Global Healthcare Conference(Globenewswire)
2024-05-17 04:12
Google DeepMind CEO: 'This Is the Next $100 Billion AI Business'(Investorplace)
2024-05-09 19:00
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting(Globenewswire)
2024-05-06 23:59
Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program(Newsdirect)
2024-04-29 19:00
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting(Globenewswire)
2024-04-22 19:00
Skye Bioscience to Present at Upcoming Investment Conferences(Globenewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.